Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

Nature Reviews Cancer

Volumn 15, Issue 5, 2015, Pages 302-310

  Furnari, Frank B ^a   Cloughesy, Timothy F ^b   Cavenee, Webster K ^a   Mischel, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EXTRACHROMOSOMAL DNA; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; LAPATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE;

ANATOMICAL CONCEPTS; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL INTERACTION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CLONAL EVOLUTION; DISEASE COURSE; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RADIOSENSITIVITY; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SUBVENTRICULAR ZONE; TUMOR MICROENVIRONMENT; UBIQUITINATION; UPREGULATION; BRAIN TUMOR; GENETICS;

BRAIN NEOPLASMS; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84928590179     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3918     Document Type: Review

References (90)

1. Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).
2. Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72-76 (2014).
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
4. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
5. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Rev. Cancer 4, 361-370 (2004).
6. Lemmon, M. A., Schlessinger, J. & Ferguson, K. M. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 6, a020768 (2014).
7. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
8. Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756-784 (2012).
9. Bonavia, R., Inda, M. M., Cavenee, W. K. & Furnari, F. B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055-4060 (2011).
10. Sturm, D. et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Rev. Cancer 14, 92-107 (2014).
11. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
12. Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1-25 (2014).
13. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
14. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
15. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
16. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
17. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
18. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
19. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
20. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014).
21. Sidransky, D. et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355, 846-847 (1992).
22. Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337 (2013).
23. Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stemlike states, and drug resistance. Mol. Cell 54, 716-727 (2014).
24. Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54-58 (2014).
25. Cleary, A. S., Leonard, T. L., Gestl, S. A. & Gunther, E. J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508, 113-117 (2014).
26. Inda, M. M. et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24, 1731-1745 (2010).
27. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
28. Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009).
29. Jung, P. et al. Isolation and in vitro expansion of human colonic stem cells. Nature Med. 17, 1225-1227 (2011).
30. Marumoto, T. et al. Development of a novel mouse glioma model using lentiviral vectors. Nature Med. 15, 110-116 (2009).
31. Friedmann-Morvinski, D. et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080-1084 (2012).
32. Wee, B., Charles, N. & Holland, E. C. Animal models to study cancer-initiating cells from glioblastoma. Front. Biosci. 16, 2243-2258 (2011).
33. Zhu, Y. et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 132, 5577-5588 (2005).
34. Jackson, E. L. et al. PDGFRα-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51, 187-199 (2006).
35. Chen, J., McKay, R. M. & Parada, L. F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149, 36-47 (2012).
36. Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277 (2002).
37. Zhu, H. et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl Acad. Sci. USA 106, 2712-2716 (2009).
38. Ciriello, G. et al. The molecular diversity of Luminal A breast tumors. Breast Cancer Res. Treat. 141, 409-420 (2013).
39. Ohgaki, H. & Kleihues, P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64, 479-489 (2005).
40. Singh, D. et al. Transforming fusions of FGFR and TAC C genes in human glioblastoma. Science 337, 1231-1235 (2012).
41. Parker, B. C., Engels, M., Annala, M. & Zhang, W. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J. Pathol. 232, 4-15 (2014).
42. Cloughesy, T. F. et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5, e8 (2008).
43. Nishikawa, R. et al. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 21, 53-56 (2004).
44. Fan, Q. W. et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24, 438-449 (2013).
45. Giacomini, C. P. et al. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet. 9, e1003464 (2013).
46. Del Vecchio, C. A. et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 32, 2670-2681 (2013).
47. Francis, J. M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956-971 (2014).
48. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
49. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009-4014 (2013).
50. Gill, B. J. et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl Acad. Sci. USA 111, 12550-12555 (2014).
51. Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl Acad. Sci. USA 109, 3041-3046 (2012).
52. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011).
53. Gini, B. & Mischel, P. S. Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discov. 4, 876-878 (2014).
54. Sanborn, J. Z. et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res. 73, 6036-6045 (2013).
55. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
56. Cheng, Y. K. et al. A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput. Biol. 8, e1002337 (2012).
57. Ozawa, T. et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26, 288-300 (2014).
58. Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53-58 (2012).
59. Nishikawa, R. et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl Acad. Sci. USA 91, 7727-7731 (1994).
60. Huang, H. S. et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935 (1997).
61. Sun, J. et al. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res. 70, 6128-6138 (2010).
62. Bendall, S. C. & Nolan, G. P. From single cells to deep phenotypes in cancer. Nature Biotech. 30, 639-647 (2012).
63. Shi, Q. et al. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc. Natl Acad. Sci. USA 109, 419-424 (2012).
64. Masui, K. et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 18, 726-739 (2013).
65. Gini, B. et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin. Cancer Res. 19, 5722-5732 (2013).
66. Masui, K., Cavenee, W. K. & Mischel, P. S. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol. Metab. 25, 364-373 (2014).
67. Yang, W. et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biol. 14, 1295-1304 (2012).
68. Yang, W. et al. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 48, 771-784 (2012).
69. L and caspase-3-like proteases. Proc. Natl Acad. Sci. USA 95, 5724-5729 (1998).
70. Tanaka, K. et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 1, 524-538 (2011).
71. Blaes, J. et al. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J. Neurooncol. 117, 25-32 (2014).
72. Groenendijk, F. H. et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int. J. Cancer 136, 1434-1444 (2014).
73. Ohashi, K., Maruvka, Y. E., Michor, F. & Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013).
74. Fenton, T. R. et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl Acad. Sci. USA 109, 14164-14169 (2012).
75. Mellinghoff, I. K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
76. Vivanco, I. et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl Acad. Sci. USA 107, 6459-6464 (2010).
77. Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
78. Akhavan, D. et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 3, 534-547 (2013).
79. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
80. Girotti, M. R. & Marais, R. Déjà vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov. 3, 487-490 (2013).
81. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
82. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
83. Vivanco, I. et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458-471 (2012).
84. Yano, S. et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res. 15, 107-111 (2005).
85. Humphrey, P. A. et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem. Biophys. Res. Commun. 178, 1413-1420 (1991).
86. Frederick, L., Wang, X. Y., Eley, G. & James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60, 1383-1387 (2000).
87. Peschard, P. et al. Structual basis for ubiquitin-mediated dimerization and activaiton of the ubiquitin protein ligase Cbl-b. Mol. Cell 27, 474-485 (2007).
88. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002).
89. Garrett, T. P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 11, 763-773 (2002).
90. Lee, J. C. et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. e485 (2006).